Atıf İçin Kopyala
Tanyeri,Tanyeri P., Buyukokuroglu M. E., Mutlu O., Ulak G., Akar F., Celikyurt I. K., ...Daha Fazla
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, cilt.138, ss.142-147, 2015 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
138
-
Basım Tarihi:
2015
-
Doi Numarası:
10.1016/j.pbb.2015.09.014
-
Dergi Adı:
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus
-
Sayfa Sayıları:
ss.142-147
-
Anahtar Kelimeler:
Ziprasidone, SCH23390, SB277011, Cognition, Morris water maze, MK-801, Mice, COGNITIVE IMPAIRMENT, RECEPTOR ANTAGONIST, CHRONIC NICOTINE, NMDA RECEPTOR, SCHIZOPHRENIA, RATS, DIZOCILPINE, GLUTAMATE, PERFORMANCE, DEFICITS
-
Kocaeli Üniversitesi Adresli:
Evet
Özet
Introduction: Patients with schizophrenia have cognitive dysfunctions: positive psychotic symptoms are the primary purposes for schizophrenia treatment Improvements in cognitive function should be a characteristic of all newly developed drugs for the treatment of schizophrenia with dementia. Thus, we investigated the effects of the second-generation antipsychotic ziprasidone, dopamine D1 antagonist SCH-23390 and dopamine D3 antagonist SB-277011 on spatial learning and memory.